Health Care & Life Sciences » Biotechnology | Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
92,273.00
19,871.00
13,944.00
91,221.00
57,284.00
110,993
Depreciation, Depletion & Amortization
742.00
928.00
921.00
2,399.00
8,132.00
7,063
Other Funds
1,727.00
1.00
-
-
-
19,831
Funds from Operations
63,195.00
25,234.00
22,351.00
58,364.00
90,930.00
133,720
Changes in Working Capital
5,246.00
17,501.00
12,173.00
8,448.00
23,710.00
4,734
Net Operating Cash Flow
57,949.00
7,733.00
34,524.00
66,812.00
114,640.00
128,986
Capital Expenditures
2,351.00
5,098.00
13,011.00
20,424.00
13,183.00
Purchase/Sale of Investments
9,761.00
211.00
26,278.00
15,540.00
73,232.00
Net Investing Cash Flow
12,112.00
4,887.00
39,289.00
35,964.00
86,415.00
Issuance/Reduction of Debt, Net
62,029.00
-
-
-
-
Net Financing Cash Flow
62,739.00
570.00
1,867.00
2,052.00
5,681.00
Net Change in Cash
7,322.00
3,416.00
2,898.00
32,900.00
33,906.00
Free Cash Flow
59,595.00
7,140.00
32,420.00
65,209.00
112,611.00
Deferred Taxes & Investment Tax Credit
-
-
-
41,787.00
21,224.00
4,167
Change in Capital Stock
2,437.00
571.00
1,867.00
2,052.00
5,681.00

About Supernus Pharmaceuticals

View Profile
Address
1550 East Gude Drive
Rockville Maryland 20850
United States
Employees -
Website http://www.supernus.com
Updated 07/08/2019
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.